Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

  • In development
  • GID-TA10311
  • Expected publication date: TBC

Status:
In progress
Decision:
Prioritised
Process:
TA

Timeline

Key events during the development of the guidance:

Date Update
28 July 2021 In progress. Topic has proceeded to terminated guidance.
10 June 2021 Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps
13 February 2018 In progress. Topic referred

For further information on our processes and methods, please see our CHTE processes and methods manual